Additionally, novel agents such as Bruton's tyrosine kinase inhibitors (BTKis) are gaining attention, particularly in cases of anti-MAG neuropathy associated with Waldenström macroglobulinemia, supported by preliminary evidence of efficacy (39–41). Here, BTK is linked to Waldenstrom macroglobulinemia.